World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   307 records for 58 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4 5 6
Recruitment statusProspective RegistrationMain ID Public TitleDate of RegistrationResults available
RecruitingYesISRCTN55209338
Parents As Partners coparenting programme with parents of infants who are more challenging to soothe
25/09/2017 
RecruitingNoCTRI/2017/09/009894
Heat therapy(agnikarma) in Tennis Elbow
22-09-2017Yes
RecruitingYesNCT02807857
A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care
Recruitment statusMain IDPublic titleDate of registrationResults available
AuthorisedEUCTR2016-000473-20-HR A prospective evaluation of natriuretic peptide based referral of chronic heart failure patients in primary care 15/12/2016 
17/06/2016 
Not recruitingYesNCT02389933
Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)
10/03/2015 
Not recruitingYesNCT02156804
A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
Recruitment statusMain IDPublic titleDate of registrationResults available
AuthorisedEUCTR2014-001286-28-ES A multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody. 06/08/2014 
AuthorisedEUCTR2014-001286-28-DK A multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody. 13/08/2014 
AuthorisedEUCTR2014-001286-28-IT A multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody. 31/07/2014 
AuthorisedEUCTR2014-001286-28-GR A multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody. 08/05/2015 
AuthorisedEUCTR2014-001286-28-NL A multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma after treament with an Anti-CTLA-4 antibody. 06/08/2014 
AuthorisedEUCTR2014-001286-28-PL A multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma after treament with an Anti-CTLA-4 antibody. 30/07/2015 
AuthorisedEUCTR2014-001286-28-FI A multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma after treament with an Anti-CTLA-4 antibody. 17/10/2014 
AuthorisedEUCTR2014-001286-28-BE A multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma after treament with an Anti-CTLA-4 antibody. 23/07/2014 
AuthorisedEUCTR2014-001286-28-SE A multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma after treament with an Anti-CTLA-4 antibody. 30/09/2014 
AuthorisedEUCTR2014-001286-28-IE A multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma after treament with an Anti-CTLA-4 antibody. 11/09/2014 
AuthorisedEUCTR2014-001286-28-AT A multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma after treament with an Anti-CTLA-4 antibody. 06/08/2014 
AuthorisedEUCTR2014-001286-28-CZ A multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma after treament with an Anti-CTLA-4 antibody. 03/02/2015 
AuthorisedEUCTR2014-001286-28-HU A multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody. 29/12/2014 
AuthorisedEUCTR2014-001286-28-PT A multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma after treament with an Anti-CTLA-4 antibody. 29/08/2014 
AuthorisedEUCTR2014-001286-28-DE A multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma after treament with an Anti-CTLA-4 antibody. 01/08/2014 
AuthorisedEUCTR2014-001286-28-GB A multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma after treament with an Anti-CTLA-4 antibody. 04/08/2014Yes
29/05/2014 
Not recruitingNoNCT02150603
Patient-Reported Outcomes in Adults With Congenital Heart Disease
21/05/2014 
RecruitingYesNCT02006069
MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing
23/09/2013 
Not recruitingYesNCT01878760
APRICOT: Anaesthesia PRactice In Children Observational Trial
28/05/2013 
Not recruitingYesNCT01694745
EUROpean Pain Audit In Neonates
25/09/2012 
Not RecruitingYesCTRI/2012/08/002905
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects with Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss due to Androgen-Deprivation Therapy
23-08-2012Yes
      
1 2 3 4 5 6
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history